{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:55:23Z","timestamp":1778781323016,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Aerie Pharmaceuticals, Inc., Irvine, CA, USA","award":["Sponsorship for this study"],"award-info":[{"award-number":["Sponsorship for this study"]}]},{"name":"Aerie Pharmaceuticals, Inc., Irvine, CA, USA","award":["article processing charges"],"award-info":[{"award-number":["article processing charges"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s12325-020-01227-y","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T18:02:49Z","timestamp":1579888969000},"page":"1114-1123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2"],"prefix":"10.1007","volume":"37","author":[{"given":"C. Ellis","family":"Wisely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-345X","authenticated-orcid":false,"given":"Huan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Heah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"1227_CR2","unstructured":"United States Food and Drug Administration. Rhopressa (netarsudil) Ophthalmic Solution. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208254Orig1s000TOC.cfm. Accessed 22 Jan 2019."},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2147\/OPTH.S154001","volume":"12","author":"L Dasso","year":"2018","unstructured":"Dasso L, Al-Khaled T, Sonty S, Aref AA. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018;12:1939\u201344.","journal-title":"Clin Ophthalmol"},{"key":"1227_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure, the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97\u2013104.","journal-title":"Am J Ophthalmol"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34:380\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"1227_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol. 2019;200:130\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1227_CR8","unstructured":"Double-masked study of PG324 ophthalmic solution in patients with glaucoma or ocular hypertension. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558400. Accessed 3 Mar 2019."},{"key":"1227_CR9","unstructured":"Double-masked study of PG324 ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02674854. Accessed 26 Jan 2019."},{"key":"1227_CR10","doi-asserted-by":"crossref","unstructured":"Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019 (in press).","DOI":"10.1016\/j.ogla.2019.03.007"},{"key":"1227_CR11","unstructured":"Safety and efficacy study of PG324 (netarsudil\/latanoprost 0.02%\/0.005%) ophthalmic solution compared to GANFORT\u00ae ophthalmic solution in open angle glaucoma or ocular hypertension. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03284853. Accessed 3 Mar 2019."},{"key":"1227_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/02713680500536738","volume":"31","author":"BA Benetz","year":"2006","unstructured":"Benetz BA, Gal RL, Ruedy KJ, et al. Specular microscopy ancillary study methods for donor endothelial cell density determination of Cornea Donor Study images. Curr Eye Res. 2006;31:319\u201327.","journal-title":"Curr Eye Res"},{"key":"1227_CR13","doi-asserted-by":"publisher","first-page":"e0136802","DOI":"10.1371\/journal.pone.0136802","volume":"10","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa H, Koizumi N, Okumura N, Suganami H, Kinoshita S. Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (ripasudil) administration: a prospective open-label clinical study. PLoS ONE. 2015;10:e0136802.","journal-title":"PLoS ONE"},{"key":"1227_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/jop.2016.0036","volume":"33","author":"R Yoo","year":"2017","unstructured":"Yoo R, Choi YA, Cho BJ. Change in central corneal thickness after the discontinuation of latanoprost in normal tension glaucoma\u2013change in central corneal thickness after stop of latanoprost. J Ocul Pharmacol Ther. 2017;33:57\u201361.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/jop.2010.0071","volume":"27","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Cho BJ. Long-term effect of latanoprost on central corneal thickness in normal tension glaucoma. J Ocul Pharmacol Ther. 2011;27:73\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/jop.2014.0109","volume":"31","author":"H Lee","year":"2015","unstructured":"Lee H, Cho BJ. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results. J Ocul Pharmacol Ther. 2015;31:152\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/jop.2013.0196","volume":"30","author":"Y Maruyama","year":"2014","unstructured":"Maruyama Y, Mori K, Ikeda Y, Ueno M, Kinoshita S. Effects of long-term topical prostaglandin therapy on central corneal thickness. J Ocul Pharmacol Ther. 2014;30:440\u20134.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ICO.0b013e3182000c27","volume":"30","author":"Y Zhong","year":"2011","unstructured":"Zhong Y, Shen X, Yu J, Tan H, Cheng Y. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea. 2011;30:861\u20134.","journal-title":"Cornea"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1442-9071.2012.02870.x","volume":"41","author":"D Viswanathan","year":"2013","unstructured":"Viswanathan D, Goldberg I, Graham SL. Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin Exp Ophthalmol. 2013;41:348\u201354.","journal-title":"Clin Exp Ophthalmol"},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archophthalmol.2010.40","volume":"128","author":"N Honda","year":"2010","unstructured":"Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol. 2010;128:466\u201371.","journal-title":"Arch Ophthalmol"},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/ICO.0b013e318285475d","volume":"32","author":"N Koizumi","year":"2013","unstructured":"Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167\u201370.","journal-title":"Cornea"},{"key":"1227_CR22","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1167\/iovs.12-11320","volume":"54","author":"N Okumura","year":"2013","unstructured":"Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Investig Ophthalmol Vis Sci. 2013;54:2493\u2013502.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1227_CR23","first-page":"976","volume":"57","author":"T Ishizaki","year":"2000","unstructured":"Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000;57:976\u201383.","journal-title":"Mol Pharmacol"},{"key":"1227_CR24","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1167\/iovs.16-20414","volume":"57","author":"LC Meekins","year":"2016","unstructured":"Meekins LC, Rosado-Adames N, Maddala R, Zhao JJ, Rao PV, Afshari NA. Corneal endothelial cell migration and proliferation enhanced by Rho kinase (ROCK) inhibitors in in vitro and in vivo models. Investig Ophthalmol Vis Sci. 2016;57:6731\u20138.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1227_CR25","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0063","author":"AS Goldstein","year":"2018","unstructured":"Goldstein AS, Aldrich BT, Skeie JM, et al. Assessing the effects of ripasudil, a novel Rho kinase inhibitor, on human corneal endothelial cell health. J Ocul Pharmacol Ther. 2018. https:\/\/doi.org\/10.1089\/jop.2018.0063.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1227_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1167\/iovs.15-18586","volume":"57","author":"N Okumura","year":"2016","unstructured":"Okumura N, Okazaki Y, Inoue R, et al. Effect of the Rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing. Investig Ophthalmol Vis Sci. 2016;57:1284\u201392.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1227_CR27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1167\/iovs.13-12225","volume":"55","author":"N Okumura","year":"2014","unstructured":"Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Investig Ophthalmol Vis Sci. 2014;55:318\u201329.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"1227_CR28","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1097\/ICO.0b013e3182281ee1","volume":"30","author":"N Okumura","year":"2011","unstructured":"Okumura N, Koizumi N, Ueno M, et al. The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction. Cornea. 2011;30(Suppl 1):S54\u20139.","journal-title":"Cornea"},{"key":"1227_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/bjo.2010.194571","volume":"95","author":"N Okumura","year":"2011","unstructured":"Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006\u20139.","journal-title":"Br J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01227-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:27:05Z","timestamp":1628612825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01227-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}